Lux Biosciences
Pioneering ophthalmic care with innovative treatments for eye diseases.
Pioneering ophthalmic care with innovative treatments for eye diseases.
Lux Biosciences is a biotechnology firm that focuses on creating treatments for eye diseases. Established in 2005 and headquartered in Jersey City, New Jersey, the company is committed to pioneering ophthalmic care with innovative treatments. Their product lineup includes various solutions such as LX201, a silicone matrix ocular implant for the extended release of cyclosporine A to the eye for up to one year; Luveniq, an oral formulation of the calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant containing voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. Lux Biosciences secured a $16.00M debt financing investment on 06 March 2012. The company operates within the Biotechnology and Life Sciences industries and continues to be a noteworthy player in the field of ophthalmic healthcare innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $16.00M | - | 06 Mar 2012 | |
| Debt Financing | $4.00M | - | 12 Dec 2011 | |
| Debt Financing | $6.00M | - | 14 Jul 2011 | |
| Debt Financing | $5.00M | - | 20 Dec 2010 | |
| Series B | $50.00M | 4 |
|
01 Oct 2009 |
No recent news or press coverage available for Lux Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
